Drugs & Targets Inrebic received European Commission approval for myelofibrosis February 12, 2021Vol.47 No.06
Drugs & TargetsFree FDA grants accelerated approval to Tepmetko for metastatic NSCLC February 05, 2021Vol.47 No.05
Drugs & TargetsFree Keytruda receives positive EU CHMP opinion for expanded approval in some cases of relapsed or refractory classical hodgkin Lymphoma February 05, 2021Vol.47 No.05
Drugs & TargetsFree Opdivo + Cabometyx receives FDA approval for advanced renal cell carcinoma January 29, 2021Vol.47 No.04
Drugs & TargetsFree European Commission approves Keytruda as first-line treatment in adult patients with MSI-H or dMMR colorectal cancer January 29, 2021Vol.47 No.04
Drugs & Targets Enhertu receives FDA approval for HER2-positive gastric adenocarcinomas January 22, 2021Vol.47 No.03
Drugs & Targets Darzalex Faspro receives accelerated approval from FDA for newly diagnosed light chain amyloidosis January 22, 2021Vol.47 No.03
Drugs & Targets FDA grants Priority Review to Opdivo as adjuvant therapy resected esophageal or gastroesophageal junction cancer January 22, 2021Vol.47 No.03
Drugs & Targets FDA grants Priority Review to Opdivo + chemotherapy as first-line treatment in metastatic gastric cancer, GEJC and EAC January 22, 2021Vol.47 No.03
Drugs & Targets FDA updates vinca alkaloid labeling for preparation in intravenous infusion bags only January 22, 2021Vol.47 No.03
